Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Value Stocks to Buy Ahead of the Fall Season

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

StockNews.com

Woman shames her 'lazy dog' who would rather starve than work for his food

A woman has playfully shamed her dog who would rather skip dinner time than work for his meal - she is now giving away his dog puzzle bowl in hope 'somebody else's dog is smarter than hers'

Daily Mirror

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

What allegations of Alzheimer's research fraud mean for patients

Alzheimer’s disease is the most prevalent form of dementia and, with a rapidly ageing global population, it is fuelling unprecedented demand for costly patient care. There have been an estimated 400 clinical studies since the first Alzheimer’s drug trial in 1987.

The Conversation

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

Monkeypox is not COVID, but need to keep a watch, says top scientist

Smallpox vaccine can protect people from getting monkeypox, says Rakesh Mishra

The Hindu

This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1

CNBC

Benzinga

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

Inverse

Food expiration dates are broken — a microbiologist explains how to fix them

Avoiding unseen food hazards is the reason people often check the dates on food packaging.

Reason

Not Even the FDA Trusts the FDA To Regulate Food Safety

The FDA has effectively thrown up its hands over its most important food-related role.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

Getting monkeypox treatment is easier, but still daunting and confusing

Though doctors and advocates have helped speed up access to the antiviral pills – of which the U.S. has enough to treat 1.7 million people – health providers are few and forms are still required.

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update

Here's a roundup of top developments in the biotech space over the last 24 hours:

Tribune News Service

Fake COVID treatments are circulating. How to spot them and get real medication

CHARLOTTE, N.C. — As COVID-19 cases soar around the country, fake treatments continue to linger on the open market, posing a safety risk to those seeking medical care.

Reason

West Virginia v. EPA: Getting to Actual Delegation

The Court should assimilate the “major questions” doctrine of West Virginia v. EPA and its precedents—including Chevron and what came even before that—to an approach that asks whether Congress has made an actual delegation. Only this will serve the relevant separation-of-powers principle.

The Independent UK

Man accused of selling bleach as Covid cure through Florida church is extradited to US

Mark Grenon, who runs a ‘non-religious church’, charged for selling toxic industrial bleach as Covid cure

WEKU

Summer boosters for people under 50 shelved in favor of updated boosters in the fall

The Biden administration is scrapping plans to offer COVID boosters for people under 50 this summer. Instead they will push for an earlier release of the next generation boosters in the fall.

1 … 179 180 181 182

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.